ReviewRheumatology and therapy2020
Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.
Review in Rheumatology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Psoriatic arthritis patients have increased morbidity already at the time of diagnosis: a case-control study.Rheumatology international · 2026Article
- Biologics reduced infections in ankylosing spondylitis and psoriatic arthritis under immunosuppressants.Journal of the Chinese Medical Association : JCMA · 2026Article
- A clinical care pathway for managing pregnancy in patients with inflammatory arthritis.Clinical rheumatology · 2026Review
- The metabolomic profile of psoriatic arthritis patients unveils the unbalance of disease-related molecules and pathways.Scientific reports · 2025Article
- The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Impaired fasting glucose and sulfonylureas increased the risk of major cardiovascular events in patients with inflammatory arthritis.Diabetology & metabolic syndrome · 2025Article
- Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation.Metabolites · 2025Review
- Predictive Modeling of the Risk of Hyperglycemia in Psoriasis Patients Using Machine Learning: A Multicenter Retrospective Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Lung involvement in patients with psoriatic arthritis.Archives of rheumatology · 2024Article
- Factors Influencing Liver Abnormalities in Psoriatic Arthritis Patients: A Comprehensive Study.Mediterranean journal of rheumatology · 2024Article
- Clinical Features and Disease Activity in Psoriatic Arthritis: A Sex-Related Perspective on Leptin and Comorbidity.Journal of clinical medicine · 2024Article
- Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated.RMD open · 2023Article
- Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis.International journal of molecular sciences · 2023Article
- Correlation Between Insulin Resistance and Psoriatic Arthritis Disease Activity: A Cross-Sectional Study.Journal of psoriasis and psoriatic arthritis · 2023Article
- Article
- Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis.Journal of clinical medicine · 2023Review
- Cardiovascular Disease and Cardiac Imaging in Inflammatory Arthritis.Life (Basel, Switzerland) · 2023Review
- Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy.Nature reviews. Rheumatology · 2023Review
- Psoriasis comorbidity management in the COVID era: a pressing challenge.Frontiers in microbiology · 2023Review
- Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates.International journal of rheumatic diseases · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriatic arthritis (PsA) is a chronic immune-mediated inflammatory spondyloarthropathy associated with psoriasis. PsA is frequently associated with metabolic disorders including, obesity, metabolic syndrome, and diabetes mellitus (DM). Type 2 DM is among the most common metabolic disorders, with a prevalence ranging from 2.4 to 14.8% in the general population.
methodsWe conducted a narrative review of the English-language studies from January 1989 to September 2019 investigating the risk of type 2 DM in patients with PsA, the pathogenic mechanism linking DM to PsA, and the effects on insulin sensitivity exerted by systemic therapies for PsA.
resultsThe prevalence of type 2 DM in patients with PsA ranges from 6.1 to 20.2%, generally higher when compared to the general population. The higher risk of DM is reported in women with more severe forms of PsA. Elevated serum levels of adipokines, including TNF-α, which inhibits the autophosphorylation of the insulin receptor and suppresses the expression of glucose transporter 4, favor insulin resistance and could partially explain the association between PsA and DM. Moreover, adiponectin and omentin, with insulin-sensitizing and anti-atherogenic properties, are decreased in patients with PsA. Some of the treatments for PsA could affect the glucose homeostasis. Systemic corticosteroids are known to impair insulin resistance, whereas apremilast (phosphodiesterase type 4 inhibitor) and TNF-α inhibitors could exert neutral effect or reduce the insulin-resistance. The role of IL-17 or IL-23 inhibitors has been marginally investigated.
conclusionsPatients affected by PsA have a higher prevalence of type 2 DM compared with the general population. The mechanism linking PsA with DM has not been completely clarified, but some of the principal mediators could be TNF-α and adipokine, especially adiponectin and omentin. Apremilast and TNF-α inhibitor may have a favorable effect and could be safely used in patients with DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.